● Goal · all research areas
Metabolic & weight research
These compounds appear in the metabolic & weight research literature. This page reports what is studied and what it costs — it is not a claim that anything works, is safe, or is for human use.
● Human trial data
What the published trials report
- GLP3 RT ~24% mean weight loss phase-2 trial, 48 weeks · PMID 37366315
- GLP2 TZ ~20% mean weight loss phase-3, head-to-head vs semaglutide · PMID 40353578
- GLP1 S ~14% mean weight loss phase-3, head-to-head vs tirzepatide · PMID 40353578
- Cagrilintide ~10% alone (~22% combined as CagriSema) phase-2 · PMID 34798060
Figures are mean weight reduction reported in each drug's trial. Retatrutide's is a phase-2 result; the tirzepatide and semaglutide figures are from a head-to-head phase-3 trial. Trials differ in size and length, so cross-comparisons are approximate — not a recommendation, and not a claim any of this applies to you.
● Compounds in this literature
7 with live prices
Ordered by evidence strength, then price.
Strong evidence
GLP2 TZ
GLP-1 / GIP dual agonist
$1.22/mg 27 vendors
Strong evidence
GLP1 S
GLP-1 agonist
$1.50/mg 19 vendors
Strong evidence
Tesamorelin
Growth-hormone secretagogue
$2.35/mg 73 vendors
Moderate evidence
GLP3 RT
GLP-1 / triple agonist
$2.25/mg 24 vendors
Moderate evidence
Cagrilintide
Amylin analog
$5.00/mg 43 vendors
Limited evidence
AOD-9604
Metabolic peptide
$3.50/mg 62 vendors
Preclinical only
MOTS-c
Mitochondrial peptide
$1.30/mg 89 vendors
● Keep exploring
Research and practical reference
All products listed are sold by third-party vendors for laboratory and research use only (RUO). Where an FDA label, a peer-reviewed study or a clinical-trial registry entry has published a dose, pepmg reports it with the source named and the tier labeled (a registry figure is marked trial registry, not peer-reviewed), because that is safer than guessing. It is a report, not medical advice and not a recommendation to use anything. pepmg sells nothing and ships nothing. Listings are price-tracking data, not endorsements.